We showed the in vivo efficacy of ETG-5773, the first selective, cross-species active, non-competitive, non-substrate-like NaCT inhibitor, and further validated this transporter as an attractive therapeutic target for metabolic diseases including MAFLD, NASH, obesity, and type 2 diabetes. This evidence concerns the gene SLC13A5 and metabolic disease.